Characterizing Perfusion and Congestion Responses to Fluid Loading in Critically Ill Septic Patients (FLUID-IMPACTS)
Sepsis is a leading cause of mortality worldwide and a major contributor to deaths in intensive care units. Early hemodynamic resuscitation, particularly fluid loading, is a cornerstone of septic shock management. However, the benefit-risk balance of fluid administration is difficult to assess in routine practice. Insufficient fluid resuscitation may result in persistent tissue hypoperfusion, organ ischemia, and multiorgan failure, whereas excessive fluid administration is associated with increased mortality, mainly due to systemic venous congestion and organ edema.
The concept of fluid tolerance, defined as the ability of a patient to receive fluids without developing harmful consequences related to fluid overload, is increasingly recognized. Nevertheless, its evaluation remains challenging because of the lack of validated tools and consensual thresholds. In addition, although several markers of tissue perfusion and systemic venous congestion have been described, their combined clinical relevance and prognostic value following fluid loading in septic shock have not been specifically evaluated.
This study aims to assess perfusion and congestion responses to fluid loading in patients with septic shock. The primary objective is to compare patients according to changes in tissue perfusion markers (lactate concentration, mottling score, capillary refill time, venous-to-arterial CO₂ gradient, and central venous oxygen saturation) and systemic venous congestion markers (central venous pressure and hepatic and portal vein Doppler indices) after fluid administration. Secondary objectives include evaluating the evolution of venous congestion markers and their association with organ dysfunction within 48 hours, the relationship between post-fluid loading congestion dynamics and 28-day mortality, and identifying pre-fluid loading predictors of patients who fail to improve tissue perfusion while exhibiting worsening venous congestion.
This is a prospective, multicenter, non-interventional observational cohort study conducted in five intensive care units. Eligible patients are adult patients with septic shock, mechanically ventilated, equipped with arterial and central venous catheters, and presenting a positive passive leg-raising test defined as an increase greater than 10% in cardiac output or left ventricular outflow tract velocity-time integral. All patients receive standard care in accordance with international guidelines, and fluid administration is entirely at the discretion of the treating physician.
Clinical, biological, hemodynamic, and echocardiographic data are collected before and after fluid loading. Patients are retrospectively classified into four groups based on the presence or absence of improvement in tissue perfusion and worsening of venous congestion. Follow-up continues until ICU discharge or day 28.
Approximately 280 patients are expected to be screened to include 170 patients. The results may help identify patients who are fluid responsive in terms of cardiac output but at risk of harmful venous congestion, supporting more individualized fluid resuscitation strategies in septic shock.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Descrizione dettagliata
All patients receive standard care in accordance with current international guidelines. The decision to administer fluids, the type of crystalloid, and the infused volume are at the discretion of the treating physician.
Study data are collected at predefined time points before and after fluid resuscitation and include routinely measured clinical, biological, and hemodynamic parameters, as well as echocardiographic Doppler indices of systemic venous congestion. Patients are retrospectively classified into four groups according to the presence or absence of improvement in tissue perfusion markers and worsening of venous congestion markers. Follow-up continues until ICU discharge or day 28, with collection of organ dysfunction scores, fluid balance, and mortality data.
Based on previous data, approximately 280 patients are expected to be screened to include 170 patients, allowing meaningful comparisons across groups. The inclusion period is 23 months, with a 28-day follow-up and a total study duration of 24 months. Statistical analyses will compare groups using appropriate parametric or nonparametric tests, survival analysis using Cox proportional hazards models, and predictive modeling assessed by ROC curve analysis.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Adrien JOSEPH, MD, PhD
- Numero di telefono: +33 1 49 09 44 09
- Email: adrien.joseph@aphp.fr
Luoghi di studio
-
-
-
Boulogne-Billancourt, Francia, 92100
- Hôpital Ambroise Paré, APHP
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Patients with septic shock, defined according to proven or suspected infection with hypotension requiring vasopressor therapy, either community or hospital onset.
- Mechanical ventilation
- Central venous catheter in the superior vena cava territory
- Arterial catheter in place
- Positive passive leg-raising (PLR) test-defined as an increase of >10% in subaortic velocity-time integral-which predicts responsiveness to fluid loading.
Exclusion Criteria:
- Contraindication to performing a passive leg-raising manoeuvre (e.g., unstable spinal fracture, intracranial hypertension, critical limb ischemia).
- Age < 18 years.
- Lack of social coverage or individuals deprived of liberty.
- Pregnant women.
- Extracorporeal membrane oxygenation (veno-venous or venoarterial)
- Cirrhosis with portal hypertension or portal vein thrombosis
- Inability to obtain non-opposition from the patient or their legal representative.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Patient classification 1 hour after completion of fluid loading
Lasso di tempo: at 1 hour
|
The primary objective of the study is to determine the proportion of patients belonging to the four categories defined by changes in tissue perfusion markers and systemic venous congestion markers, one hour after fluid load. Group 1 : Improvement in tissue perfusion markers with no worsening of systemic venous congestion markers Group 2 : Improvement in tissue perfusion markers with worsening of systemic venous congestion markers Group 3 : No improvement in tissue perfusion markers with no worsening of systemic venous congestion markers Group 4 : No improvement in tissue perfusion markers with worsening of systemic venous congestion markers Tissue perfusion will be assessed using blood lactate concentration, central venous oxygen saturation, venous-to-arterial carbon dioxide difference, mottling score and capillary refill time. Systemic venous congestion will be assessed using portal vein pulsatility, hepatic vein doppler S/D ratio and central venous pressure. |
at 1 hour
|
|
Change in SOFA score from baseline to 48 hours after fluid loading
Lasso di tempo: at 48 hours
|
Assessing the association between the 4 group classification mentionned above and organ dysfunction (defined as a increase in SOFA score components) within the 48 hours following fluid administration.
|
at 48 hours
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Day 28 mortality
Lasso di tempo: at 28 days
|
Assessing the association between the 4 group classification mentionned above and day-28 mortality.
|
at 28 days
|
|
Identifying pre-fluid loading predictors
Lasso di tempo: at 28 days
|
Identifying pre-fluid loading predictors of belonging to the subgroup of patients who fail to show improvement in tissue perfusion and who demonstrate worsening systemic venous congestion.
|
at 28 days
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 24AJH-FLUID-IMPACTS
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .